These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 36965751

  • 1. Nutritional Status is Associated With Preserved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease.
    Lee J, Ryu H, Kim YC, Park HC, Ahn C, Lee KB, Kim YH, Kim Y, Han S, Bae EH, Oh KH, Oh YK.
    J Ren Nutr; 2023 Jul; 33(4):529-537. PubMed ID: 36965751
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE.
    Clin J Am Soc Nephrol; 2018 Aug 07; 13(8):1153-1161. PubMed ID: 30026287
    [Abstract] [Full Text] [Related]

  • 3. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S, Muto S, Kawano H, Okada T, Shibasaki Y, Nakajima K, Ibuki T.
    Clin Exp Nephrol; 2021 May 07; 25(5):467-478. PubMed ID: 33471240
    [Abstract] [Full Text] [Related]

  • 4. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, TEMPO 3:4 Trial Investigators.
    Clin J Am Soc Nephrol; 2016 May 06; 11(5):803-811. PubMed ID: 26912543
    [Abstract] [Full Text] [Related]

  • 5. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M, Kogure Y, Hoshino J, Ubara Y, Mizuno H, Sekine A, Kawada M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Takaichi K.
    J Nephrol; 2018 Dec 06; 31(6):961-966. PubMed ID: 30357715
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of tolvaptan on renal replacement therapy in patients with autosomal dominant polycystic kidney disease: a retrospective cohort study from the TriNetX global collaborative network.
    Wu MJ, Chen CH, Tsai SF.
    Ren Fail; 2024 Dec 06; 46(2):2412721. PubMed ID: 39422218
    [Abstract] [Full Text] [Related]

  • 7. Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease.
    Ryu H, Kim H, Park HC, Kim H, Cho EJ, Lee KB, Chung W, Oh KH, Cho JY, Hwang YH, Ahn C.
    BMC Nephrol; 2017 Jan 14; 18(1):22. PubMed ID: 28088190
    [Abstract] [Full Text] [Related]

  • 8. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H, McEwan P, Hamilton K, O'Reilly K.
    BMC Nephrol; 2019 Apr 23; 20(1):136. PubMed ID: 31014270
    [Abstract] [Full Text] [Related]

  • 9. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.
    Am J Kidney Dis; 2015 Jun 23; 65(6):833-41. PubMed ID: 25600953
    [Abstract] [Full Text] [Related]

  • 10. Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.
    Nowak KL, Moretti F, Bussola N, Steele CN, Gregory AV, Kline TL, Ramanathan S, Trapletti G, Furlanello C, McCormick L, Chonchol M.
    Am J Kidney Dis; 2024 Sep 23; 84(3):275-285.e1. PubMed ID: 38608748
    [Abstract] [Full Text] [Related]

  • 11. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS, TEMPOFormula and 156-05-002 Study Investigators.
    Clin J Am Soc Nephrol; 2011 Oct 23; 6(10):2499-507. PubMed ID: 21903984
    [Abstract] [Full Text] [Related]

  • 12. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.
    Nephrol Dial Transplant; 2018 Apr 01; 33(4):645-652. PubMed ID: 28992127
    [Abstract] [Full Text] [Related]

  • 13. Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease.
    Akihisa T, Kataoka H, Makabe S, Manabe S, Yoshida R, Ushio Y, Sato M, Tsuchiya K, Mochizuki T, Nitta K.
    Clin Exp Nephrol; 2022 Jun 01; 26(6):540-551. PubMed ID: 35165806
    [Abstract] [Full Text] [Related]

  • 14. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.
    Am J Kidney Dis; 2011 May 01; 57(5):692-9. PubMed ID: 21333426
    [Abstract] [Full Text] [Related]

  • 15. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O, TEMPO 3:4 Investigators.
    Kidney Int; 2019 Jul 01; 96(1):159-169. PubMed ID: 30898339
    [Abstract] [Full Text] [Related]

  • 16. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
    Muto S, Okada T, Shibasaki Y, Ibuki T, Horie S.
    Clin Exp Nephrol; 2021 Sep 01; 25(9):1003-1010. PubMed ID: 34089122
    [Abstract] [Full Text] [Related]

  • 17. Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Geurts F, Xue L, Kramers BJ, Zietse R, Gansevoort RT, Fenton RA, Meijer E, Salih M, Hoorn EJ, DIPAK Consortium.
    Clin J Am Soc Nephrol; 2023 Nov 01; 18(11):1426-1434. PubMed ID: 37574650
    [Abstract] [Full Text] [Related]

  • 18. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
    Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O, REPRISE Trial Investigators.
    Am J Nephrol; 2017 Nov 01; 45(3):257-266. PubMed ID: 28166521
    [Abstract] [Full Text] [Related]

  • 19. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G, Asselin-Thompstone L, Mac-Way F, René de Cotret P, Lacroix C, Desmeules S, Agharazii M.
    Int Urol Nephrol; 2020 Feb 01; 52(2):343-349. PubMed ID: 32008201
    [Abstract] [Full Text] [Related]

  • 20. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators.
    N Engl J Med; 2012 Dec 20; 367(25):2407-18. PubMed ID: 23121377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.